Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor-neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear. METHODS: We randomly assigned 4822 patients with New York Heart Association (NYHA) class II to IV heart failure, ejection fraction of 45% or higher, elevated level of natriuretic peptides, and structural heart disease to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg twice daily). The primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes. Primary outcome components, secondary outcomes (including NYHA class change, worsening renal function, and change in Kansas City Cardiomyopathy Questionnaire [KCCQ] clinical summary score [scale, 0 to 100, with higher scores indicating fewer symptoms and physical limitations]), and safety were also assessed. RESULTS: There were 894 primary events in 526 patients in the sacubitril-valsartan group and 1009 primary events in 557 patients in the valsartan group (rate ratio, 0.87; 95% confidence interval [CI], 0.75 to 1.01; P = 0.06). The incidence of death from cardiovascular causes was 8.5% in the sacubitril-valsartan group and 8.9% in the valsartan group (hazard ratio, 0.95; 95% CI, 0.79 to 1.16); there were 690 and 797 total hospitalizations for heart failure, respectively (rate ratio, 0.85; 95% CI, 0.72 to 1.00). NYHA class improved in 15.0% of the patients in the sacubitril-valsartan group and in 12.6% of those in the valsartan group (odds ratio, 1.45; 95% CI, 1.13 to 1.86); renal function worsened in 1.4% and 2.7%, respectively (hazard ratio, 0.50; 95% CI, 0.33 to 0.77). The mean change in the KCCQ clinical summary score at 8 months was 1.0 point (95% CI, 0.0 to 2.1) higher in the sacubitril-valsartan group. Patients in the sacubitril-valsartan group had a higher incidence of hypotension and angioedema and a lower incidence of hyperkalemia. Among 12 prespecified subgroups, there was suggestion of heterogeneity with possible benefit with sacubitril-valsartan in patients with lower ejection fraction and in women. CONCLUSIONS: Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart failure and an ejection fraction of 45% or higher. (Funded by Novartis; PARAGON-HF ClinicalTrials.gov number, NCT01920711.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the PARAGON-HF trial (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction), neprilysin inhibition reduced the risk of cardiovascular death and total hospitalizations by 13%, improved KCCQ by 1.0 points, and had no overall effect on the EuroQol Visual Analog Scale.3,9”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationYusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationIrbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Zile, M. R., Baicu, C. F., & Gaasch, W. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032566 · Cited by 1,563
Self-citationThe perindopril in elderly people with chronic heart failure (PEP-CHF) study
Cleland, J. G. F. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl250 · Cited by 1,508
Self-citationSolomon, S. D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., Shi, V., Bransford, T., Takeuchi, M., Gong, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61227-6 · Cited by 1,173
Self-citationPhenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction
Shah, S. J., Katz, D. H., Selvaraj, S., Burke, M. A., Yancy, C. W., Gheorghiade, M., Bonow, R. O., Huang, C.-C., & Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.114.010637 · Cited by 1,157
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Research works printed but not linked: 1
- Cowling BJ, Hutton JL, Shaw JEH. Joint modeling of event counts and sur- vival times. Appl Stat 2006; 55: 31-9.
Cited by
Items 501–600 of 1,000
Velicki, L., Popović, D., Okwose, N. C., Preveden, A., Tesic, M. B., Tafelmeier, M., Charman, S. J., Barlocco, F., MacGowan, G. A., Seferovic, P. M., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3291 · Cited by 30
Lassen, M. C. H., Ostrominski, J. W., Claggett, B. L., Packer, M., Zile, M. R., Desai, A. S., Shah, A. M., Čikeš, M., Merkely, B. P., Gori, M., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3304 · Cited by 30
Self-citationFormiga, F., Núñez, J. E., Moraga, M. J. C., Marcos, M. C., Egocheaga, M. I., García‐Prieto, C. F., Trueba-Sáiz, Á., Gilarranz, A. M., & Rodríguez, J. M. F. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10360-z · Cited by 35
“…atrial fibrillation; > 900 pg/mL], DELIVER [NT-proBNP: sinus rhythm: ≥ 300 pg/mL; atrial fibrillation; ≥ 600 pg/mL], and PARAGON-HF [NT-proBNP: sinus rhythm: > 300 pg/mL; atrial fibrillation; > 900 pg/mL]) have defined higher cut-off levels of NT-proBNP as inclusion criteria (Table 3) [4, 5, 23].”
Matsumoto, S., McMurray, J. J. V., Nasu, T., Ishii, S., Kagiyama, N., Kida, K., Fujimoto, W., Kikuchi, A., Ijichi, T., Shibata, T., et al. (2023) · Journal of Cardiology · doi:10.1016/j.jjcc.2023.11.005 · Cited by 30
Self-citationIrving, C. A., Azeka, E., Adorisio, R., Blume, E. D., Bogle, C., Chubb, H., Conway, J. L., Cousino, M. K., Edelson, J. B., Ford, K., et al. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.06.003 · Cited by 33
Rosano, G. M. C., Quek, D. K., & Martínez, F. A. (2020) · Cardiac failure review · doi:10.15420/cfr.2020.23 · Cited by 31
“The much‐anticipated Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON‐HF) trial of sacubitril–valsartan in patients with HFpEF missed its primary endpoint, although there were some indicators of efficacy in specific pati…”
BackgroundWeisbrod, D. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.590534 · Cited by 30
Nordén, E. S., Bendiksen, B. A., Andresen, H., Bergo, K. K., Espe, E. K. S., Hasic, A., Hauge‐Iversen, I. M., Veras, I., Hussain, R. I., Sjaastad, I., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13177 · Cited by 28
“The follow-up trial in HFpEF patients, PARAGON-HF, narrowly missed its primary endpoint, while sub-analyses indicated a possible treatment effect in the lower ranges of ejection fraction (EF), leaving uncertainty regarding the use of ARNi in patients with HFpEF.(4) Such lack of clear treatment benefit has been seen in…”
BackgroundResultInfluentialEffects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
Selvaraj, S., Claggett, B. L., Packer, M., Zannad, F. M., Anand, I. S., Pieske, B. M., Zhao, Z., Shi, V. C., Lefkowitz, M. P., McMurray, J. J. V., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022069 · Cited by 30
Self-citationHeart Failure With Mid-range Ejection Fraction: A Distinctive Subtype or a Transitional Stage?
Zhou, Q., Li, P., Zhao, H., Xu, X., Li, S., Zhao, J., Xu, D., & Zeng, Q. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.678121 · Cited by 31
“However, in subgroup analyses, a potential benefit was observed in patients with a relatively lower LVEF (45–57%), suggesting that patients with HFmrEF characterized by a mildly reduced LVEF may benefit from sacubitril/valsartan (55, 56).”
BackgroundRenal Dysfunction and Heart Failure with Preserved Ejection Fraction
Ananthram, M. G., & Gottlieb, S. S. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.03.005 · Cited by 32
Neues zur Diagnostik und Therapie der Herzinsuffizienz
Wintrich, J., Berger, A.-K., Bewarder, Y., Emrich, I. E., Slawik, J., & Böhm, M. (2021) · Herz · doi:10.1007/s00059-021-05062-x · Cited by 41
“Bei Nachweis einer HFpEF sollte stets eine finale ätiologischeAbklärung (F2) durchgeführt werden Symptome Orthopnoe, Belastungsdyspnoe (NYHA II–III), eingeschränkte Belastbarkeit Komorbiditäten, Risikofaktoren Arterielle Hypertonie, Diabetesmellitus, Adipositas, Vorhofflimmern, Alter EKG Positive LVH-Indizes, P mitral…”
BackgroundInfluentialKing, N. E., & Brittain, E. L. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12028 · Cited by 30
The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review
Zhang, R., Sun, X., Li, Y., He, W.-Z., Zhu, H., Liu, B., & Zhang, A. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211058681 · Cited by 34
Maurer, M. S., Dunnmon, P., Fontana, M., Quarta, C. C., Prasad, K., Witteles, R. M., Rapezzi, C., Signorovitch, J., Lousada, I., & Merlini, G. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.009038 · Cited by 29
Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes
Claggett, B. L., McCaw, Z. R., Tian, L., McMurray, J. J. V., Jhund, P. S., Uno, H., Pfeffer, M. A., Solomon, S. D., & Wei, L. (2022) · NEJM Evidence · doi:10.1056/evidoa2200047 · Cited by 29
Self-citationHarrington, J., Petrie, M. C., Anker, S. D., Bhatt, D. L., Jones, W. S., Udell, J. A., Hernandez, A. F., & Butler, J. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.2847 · Cited by 31
Köseoğlu, F. D., & Özlek, B. (2024) · Diagnostics · doi:10.3390/diagnostics14020209 · Cited by 37
“It appears that the prevailing drug therapies that have proven successful in addressing HFrEF may not yield comparable outcomes when applied to HFpEF treatment [16–18].”
BackgroundMebazaa, A., Davison, B. A., Biegus, J., Edwards, C., Murtagh, G., Varounis, C., Hayrapetyan, H., Sisakian, H. S., Ter‐Grigoryan, V. R., Takagi, K., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3265 · Cited by 28
Ge, J. (2020) · Cardiology Journal · doi:10.5603/cj.2020.0023 · Cited by 28
“With the publication of the PARAGON-HF (The Prospective Comparison of ARNI [angiotensin receptor–neprilysin inhibitor] with ARB [angiotensin-receptor blockers] Global Outcomes in Heart Failure with Preserved Ejection Fraction) trial during the European Society of Cardiology Congress 2019 [1], cardiologists again faced…”
MethodSelf-citationThe management of atrial fibrillation in heart failure: an expert panel consensus
Farmakis, D. T., Chrysohoou, C. A., Giamouzis, G., Giannakoulas, G. A., Hamilos, M. I., Naka, K. Κ., Tzeis, S. E., Xydonas, S., Karavidas, A. I., & Parissis, J. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09978-0 · Cited by 34
Butt, J. H., Jhund, P. S., Henderson, A. D., Claggett, B. L., Chiang, C., Linssen, G. C. M., Saldarriaga, C., Saraiva, J. F. K., Sato, N., Schou, M., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.1775 · Cited by 28
Self-citationLumpers and splitters: the bumpy road to precision medicine
Lüscher, T. F. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz644 · Cited by 27
Machine Learning in Cardiology—Ensuring Clinical Impact Lives Up to the Hype
Russak, A. J., Chaudhry, F., Freitas, J. K. D., Baron, G., Chaudhry, F. F., Bienstock, S., Paranjpe, I., Vaid, A., Ali, M., Zhao, S., et al. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420928651 · Cited by 31
“28-32 In imaging, cardiac magnetic resonance imaging has led to improved recognition of viable myocardium in the setting of previous coronary ischemia 33 but challenges remain with regard to making these advanced imaging modalities readily accessible to patients in rural areas.”
BackgroundDevice-based treatment options for heart failure with preserved ejection fraction
Miyagi, C., Miyamoto, T., Karimov, J. H., Starling, R. C., & Fukamachi, K. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10067-5 · Cited by 30
Adams, V., Wunderlich, S., Mangner, N., Hommel, J., Esefeld, K., Gielen, S., Halle, M., Ellingsen, Ø., Craenenbroeck, E. M. V., Wisløff, U., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13405 · Cited by 27
Self-citationDiseases of the Cardiovascular System
Lockhart, P. B., & Sun, Y. (2021) · Wiley eBooks · doi:10.1002/9781119597797.ch14 · Cited by 32
Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity
Dhore-Patil, A., Thannoun, T., Samson, R., & Jemtel, T. H. L. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.785879 · Cited by 30
Interrelation between heart failure with preserved ejection fraction and renal impairment
Joslin, J. R., Lioudaki, E., & Androulakis, E. S. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2302069 · Cited by 29
“for heart failure [35] No differing treatment effect between those with eGFR”
BackgroundInfluentialClassifying heart failure based on ejection fraction: imperfect but enduring
Khan, M. S., Shahid, I., Fonarow, G. C., & Greene, S. J. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2470 · Cited by 30
McNaughton, C. D., McConnachie, A., Cleland, J. G. F., Spertus, J. A., Angermann, C. E., Duklas, P., Tromp, J., Lam, C. S. P., Filippatos, G. S., Dahlström, U., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2508 · Cited by 35
Self-citationDulce, R. A., Kanashiro‐Takeuchi, R. M., Takeuchi, L. M., Salerno, A. G., Wanschel, A. C. B. A., Kulandavelu, S., Balkan, W., Zuttion, M. S. S. R., Cai, R., Schally, A. V., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac098 · Cited by 27
Gan, L., Lyu, X., Yang, X., Zhao, Z., Tang, Y., Chen, Y., Yao, Y., Hong, F., Xu, Z., Chen, J., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.877237 · Cited by 29
“73 m2) in the PARAGON-HF study showed that ARNI significantly reduced the risk of the renal composite endpoint by 50% compared with ARB (30).”
BackgroundCardiac rehabilitation utilization, barriers, and outcomes among patients with heart failure
Nelson, R. K., Solomon, R. A., Hosmer, E. E., & Zuhl, M. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10309-2 · Cited by 28
“Unfortunately, the role of MRA and ARNi in HFpEF remains unclear, with trials like TOPCAT and PARAGONHF unable to offer definitive proof of benefit in regards to hospitalizations and mortality [18, 19].”
ResultAlanazi, F., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alexiou, A. T., Papadakis, M., Ogaly, H. A., Alanazi, Y. A., Saad, H. M., & Batiha, G. E. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13389 · Cited by 29
“Indeed, NEP is mainly involved in neurohumoral activation and regulation of the sympathetic nervous system and renin-angiotensin system (RAS) in different diseases including heart failure.(2,4,7) Higher expression of NEP is associated with poor prognostic outcomes in patients with heart failure.”
BackgroundAmano, M., Izumi, C., Watanabe, H., Ozasa, N., Morimoto, T., Bao, B., Suwa, S., Miyake, M., Tamura, T., Nakagawa, Y., et al. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.04.042 · Cited by 29
Potential molecular mechanism underlying cardiac fibrosis in diabetes mellitus: a narrative review
Ridwan, M. Q., Dimiati, H., Syukri, M., & Lesmana, R. (2023) · The Egyptian Heart Journal · doi:10.1186/s43044-023-00376-z · Cited by 32
Triposkiadis, F. K., Sarafidis, P. A., Briasoulis, Α., Magouliotis, D. E., Athanasiou, T., Skoularigis, J. S., & Xanthopoulos, A. V. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155090 · Cited by 34
Jirak, P., Pistulli, R., Lichtenauer, M., Wernly, B., Paar, V., Motloch, L. J., Rezar, R., Jung, C., Hoppe, U. C., Schulze, P. C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041130 · Cited by 29
“Despite huge efforts, studies failed to show a significant prognostic benefit of pharmaceutical therapies in HFpEF, with the “PARAGON-Trial” as most prominent example [8].”
BackgroundJang, S., Ogunmoroti, O., Ndumele, C. E., Zhao, D., Rao, V. N., Fashanu, O. E., Tibuakuu, M., Otvos, J. D., Benson, E., Ouyang, P., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007067 · Cited by 32
Soluble Neprilysin and Corin Concentrations in Relation to Clinical Outcome in Chronic Heart Failure
Gommans, D. H. F., Revuelta‐López, E., Lupón, J., Cserkóová, A., Domingo, M., Vart, P., van Royen, N., Bayés‐Genís, A., & van Kimmenade, R. R. J. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.08.015 · Cited by 27
Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats
Zhang, W., Liu, J., Fu, Y., Ji, H., Fang, Z., Zhou, W., Fan, H., Zhang, Y., Liao, Y., Yang, T., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.600953 · Cited by 27
“One clinical study reported that Sac/Val did not significantly lower the total rate of hospitalizations and death due to HF in patients with HFpEF (Solomon et al., 2019).”
BackgroundWang, M., Shan, Y., Wu, C., Cao, P., Sun, W., Han, J., Shen, L., Chen, J., Yu, P., & Chen, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.626375 · Cited by 27
“, 2013), ARNI (Solomon et al., 2019) and other drugs used for HFrEF have been proved to be ineffective for HFpEF, in recent years, scholars have begun to seek specific drugs based on the pathophysiological mechanism of HFpEF to achieve treatment goal.”
BackgroundInfluentialObesity in Heart Failure with Preserved Ejection Fraction: Insights from the REDUCE LAP-HF II Trial
Litwin, S. E., Komtebedde, J., Seidler, T., Borlaug, B. A., Winkler, S., Solomon, S. D., Eicher, J.-C., Mazimba, S., Khawash, R., Sverdlov, A. L., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3092 · Cited by 26
Self-citationDeciphering the Dilemma: Anticoagulation for Heart Failure With Preserved Ejection Fraction (HFpEF)
Jyotsna, F., Mahfooz, K., Sohail, H., Kumar, S., Adeeb, M., Dev, A., Kumar, R., Rekha, F., Varrassi, G., Khatri, M., et al. (2023) · Cureus · doi:10.7759/cureus.43279 · Cited by 26
“However, these guidelines do not offer specific recommendations regarding anticoagulation therapy for individuals with HFpEF [45].”
BackgroundMartinez, C. S., Zheng, A., & Xiao, Q. (2024) · Antioxidants · doi:10.3390/antiox13111330 · Cited by 33
Rasalam, R. R., Sindone, A. P., Deed, G., Audehm, R. G., & Atherton, J. J. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15205 · Cited by 28
Zile, M. R., Abraham, W. T., Stevenson, L. W., Costanzo, M. R., Angermann, C. E., Mehra, M. R., Desai, A. S., Ducharme, A., Johnson, N., Henderson, J., et al. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.012754 · Cited by 26
Self-citationEffect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF
Zannad, F. M., Reddy, Y. N. V., Barash, I., Anstrom, K. J., Bonaca, M. P., Borentain, M., Corda, S., Teixeira, P. P., Ezekowitz, J. A., Gates, D. F., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.051 · Cited by 28
Self-citationSchulz, M., Griese‐Mammen, N., Schumacher, P. M., Anker, S. D., Koehler, F., Ruckes, C., Rettig‐Ewen, V., Wachter, R., Trenk, D., Böhm, M., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12904 · Cited by 31
Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study
Felker, G. M., Butler, J., Januzzi, J. L., Desai, A. S., McMurray, J. J. V., & Solomon, S. D. (2021) · Circulation · doi:10.1161/circulationaha.121.054496 · Cited by 26
Self-citationLiu, X., Liu, H., Wang, L., Zhang, L., & Xu, Q. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263131 · Cited by 27
“PARAGON-HF, 2019 [14] 4822 HFpEF I-IV 72.”
BackgroundMethodInfluentialSudden Death and Ventricular Arrhythmias in Heart Failure With Preserved Ejection Fraction
Cho, J. H. (2022) · Korean Circulation Journal · doi:10.4070/kcj.2021.0420 · Cited by 30
The history and mystery of sacubitril/valsartan: From clinical trial to the real world
Zhang, M., Zou, Y., Li, Y., Wang, H., Sun, W., & Liu, B. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1102521 · Cited by 29
“The results of the study published in 2019 suggested that Sacubitril/valsartan has fewer primary outcome events than valsartan (51).”
ResultAngiotensin-Converting Enzyme and Heart Failure
Álvarez-Zaballos, S., & Martínez‐Sellés, M. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2807150 · Cited by 26
“As for clinical outcomes, the Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction (PARAGON-HF) trial failed to show significant differences in the primary endpoint of mortality and HF hospitalization [81].”
ResultSacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to <30 mL/min/1.73 m2
Chatur, S., Beldhuis, I. E., Claggett, B. L., McCausland, F. R., Neuen, B. L., Desai, A. S., Rouleau, J. L., Zile, M. R., Packer, M., Pfeffer, M. A., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.03.014 · Cited by 31
Self-citationChimura, M., Petrie, M. C., Schou, M., Martínez, F. A., Henderson, A. D., Claggett, B. L., Desai, A. S., Kolkhof, P., Viswanathan, P., Lage, A. Z., et al. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.012437 · Cited by 27
Self-citationTailoring Medical Therapy for Heart Failure with Preserved Ejection Fraction
Inciardi, R. M., Riccardi, M., Savarese, G., Metra, M., Vaduganathan, M., & Solomon, S. D. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3558 · Cited by 26
Self-citationDzhioeva, O. N., & Belyavskiy, E. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s207117 · Cited by 29
Report from the 5th cardiovascular outcome trial (CVOT) summit
Schnell, O., Standl, E., Cos, X., Heerspink, H. J. L., Itzhak, B., Lalic, N. M., Nauck, M. A., & Ceriello, A. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01022-7 · Cited by 28
Revisiting resistant hypertension: a comprehensive review
Chan, R., Helmeczi, W., & Hiremath, S. S. (2023) · Internal Medicine Journal · doi:10.1111/imj.16189 · Cited by 28
Kondo, T., Jhund, P. S., Gasparyan, S. B., Yang, M., Claggett, B. L., McCausland, F. R., Tolomeo, P., Vadagunathan, M., Heerspink, H. J. L., Solomon, S. D., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02941-8 · Cited by 26
Self-citationOskouie, S. K., Pandey, A., Sauer, A. J., Greene, S. J., Müllens, W., Khan, M. S., Quinn, K. L., Ho, J. E., Albert, N. M., & Spall, H. G. C. V. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101131 · Cited by 26
Matsumoto, S., Henderson, A. D., Shen, L., Kondo, T., Yang, M., Campbell, R. T., Anand, I. S., de Boer, R. A., Desai, A. S., Lam, C. S. P., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3383 · Cited by 27
Self-citationDiabetic cardiomyopathy: insights into pathophysiology, diagnosis and clinical management
Chen, D., Sindone, A. P., Huang, M., Peter, K., & Jenkins, A. J. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.06.013 · Cited by 27
van Weperen, V. Y. H., & Vaseghi, M. (2025) · Nature reviews. Neuroscience · doi:10.1038/s41583-025-01000-6 · Cited by 29
Lam, C. S. P., Wood, R. P., Vaduganathan, M., Bueno, H., Chin, A., Saraiva, G. L., Sörstadius, E., Tritton, T., Thomas, J., & Qin, L. (2021) · Clinical Cardiology · doi:10.1002/clc.23585 · Cited by 25
“Inclusion of urgent HF visits in a sensitivity analysis of the PARAGON-HF trial resulted in statistically significant differences in the primary outcome for a study that otherwise failed to show differences between arms.(13) In that study, sacubitril–valsartan did not significantly lower rates of total hHFs and death…”
ResultSelf-citationWang, X., Zhang, C., & Editing Group of the Chinese Expert Consensus on the Diagnosis and Treatment of Chronic Heart Failure in Elderly Patients (2022) · Aging Medicine · doi:10.1002/agm2.12215 · Cited by 27
Wang, N., Evans, J., Sawant, S., Sindone, J., & Lal, S. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10275-1 · Cited by 27
Zhou, W., Yang, X., Jin, J., Cheng, M., Li, Y., Bai, Y., & Xu, J. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03599-w · Cited by 26
“Three of the trials (PARADIGM-HF, PIONEER-HF and PARALELL-HF trial) compared sacubitril/valsartan with ACEI [14, 16, 17], and the other three (PARAGON-HF, PARAMOUNT trial and UK HARP-III trial) compared sacubitril/valsartan with ARB [11, 13, 15].”
MacDonald, B. J., Virani, S., Zieroth, S. R., & Turgeon, R. D. (2023) · CJC Open · doi:10.1016/j.cjco.2023.05.008 · Cited by 30
Doiron, J. E., Li, Z., Yu, X., LaPenna, K. B., Quiriarte, H. D., Allerton, T. D., Koul, K., Malek, A. J., Shah, S. J., Sharp, T. E., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032646 · Cited by 26
Self-citationThe impact of female sex hormones on cardiovascular disease: from mechanisms to hormone therapy
Kan, Y., Peng, Y., Zhao, Z.-H., Dong, S., Xu, Y.-X., Ma, X., Liu, X., Liu, Y., & Yu-Jie, Z. H. O. U. (2024) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2024.06.003 · Cited by 28
Impact of Sacubitril-Valsartan on Markers of Glomerular Function
Tersalvi, G., Dauw, J., Martens, P., & Müllens, W. (2020) · Current Heart Failure Reports · doi:10.1007/s11897-020-00463-1 · Cited by 25
Haji, K., Marwick, T. H., Stewart, S., Carrington, M. J., Chan, Y., Chan, W., Huynh, Q. L., Neil, C., & Wong, C. Y. (2021) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2021.09.003 · Cited by 27
Serotonin release in nucleus of the solitary tract and its modulation by antitussive drugs.
Kamei, J., Mori, T., Igarashi, H., & Kasuya, Y. (1992) · PubMed · Cited by 25
Correia, E. T. D. O., & Mesquita, E. T. (2022) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210753 · Cited by 25
Chiang, C., Hung, C., Wu, Y., Lin, T., Ueng, K., Sung, S., Wu, C., Chao, T., Lin, H., Lin, Y., et al. (2023) · PubMed Central · doi:10.6515/acs.202305_39(3).20230301a · Cited by 30
HFpEF and sex: understanding the role of sex differences
Smereka, Y., & Ezekowitz, J. A. (2024) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2023-0403 · Cited by 26
Management of Heart Failure in a Resource-Limited Setting: Expert Opinion from India
Jain, P., Guha, S., Kumar, S., Sawhney, J. P. S., Sharma, K. H., Sureshkumar, K. P., Mehta, A., Dhediya, R., Gaurav, K., Mittal, R., et al. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00367-4 · Cited by 24
Quiriarte, H. D., Noland, R. C., Stampley, J., Davis, G., Li, Z., Cho, E., Kim, Y., Doiron, J. E., Spielmann, G., Ghosh, S. K., et al. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.07.009 · Cited by 26
Self-citationMacrophage pyroptosis and its crucial role in ALI/ARDS
Cai, Y., Shang, L., Zhou, F., Zhang, M., Li, J., Wang, S., Lin, Q., Huang, J., & Yang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1530849 · Cited by 38
“Sacubitril/valsartan (SV) is an angiotensin receptor-neprilysin inhibitor used for treating heart failure in the clinical settings (171).”
Worsening heart failure: progress, pitfalls, and perspectives
Fonseca, C., Rui, B., Franco, F., Brenda, M., Pimenta, J., Sarmento, P., Silva‐Cardoso, J., & Brito, D. A. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10497-z · Cited by 26
Role of renin–angiotensin–aldosterone system inhibitors in heart failure and chronic kidney disease
Singhania, N., Bansal, S. K., Mohandas, S., Nimmatoori, D. P., Ejaz, A. A., & Singhania, G. (2020) · Drugs in Context · doi:10.7573/dic.2020-7-3 · Cited by 25
Alves-Lopes, R., Montezano, A. C. I., Neves, K. B., Harvey, A., Rios, F. J. O., Skiba, D. S., Arendse, L. B., Guzik, T. J., Graham, D., Poglitsch, M., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17041 · Cited by 26
Zhang, X.-J., Zhou, Y., & Ma, R. (2021) · Journal of diabetes and its complications · doi:10.1016/j.jdiacomp.2021.108056 · Cited by 20
Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial
Spall, H. G. C. V., DeFilippis, E. M., Lee, S. F., Oz, U. E., Perez, R., Healey, J. S., Allen, L. A., Voors, A. A., Ko, D. T., Thabane, L., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008548 · Cited by 25
Large animal models of heart failure with preserved ejection fraction
Miyagi, C., Miyamoto, T., Kuroda, T., Karimov, J. H., Starling, R. C., & Fukamachi, K. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10184-9 · Cited by 25
Age and Sex Differences in Heart Failure With Preserved Ejection Fraction
Kobak, K. A., Zarzycka, W., & Chiao, Y. A. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.811436 · Cited by 26
“For example, the PARAGONHF trial showed that sacubitril–valsartan treatment did not reduce the rate of total hospitalizations for HF and death from cardiovascular causes among patients with HF with a LVEF of 45% or higher (Solomon et al., 2019).”
MethodExercise Blood Pressure in Heart Failure With Preserved and Reduced Ejection Fraction
Namasivayam, M. J., Lau, E. S., Zern, E. K., Schoenike, M., Hardin, K. M., Sbarbaro, J. A., Cunningham, T. F., Farrell, R., Rouvina, J. N., Kowal, A., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.01.012 · Cited by 24
Yano, M., Nishino, M., Ukita, K., Kawamura, A., Nakamura, H., Matsuhiro, Y., Yasumoto, K., Tsuda, M., Okamoto, N., Matsunaga‐Lee, Y., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.06.061 · Cited by 24
Guo, H., Wang, J., Peng, G.-C., Li, P., & Zhu, M. (2022) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-022-2892-5 · Cited by 24
“However , modern Western medic ine has no effective treatment to lessen the associated rates of hospitalization and mortality.((1,13,14))”
BackgroundWu, H., Tang, L., Wang, X., Li, L.-P., Chen, X., He, Y., Yang, D., Shi, Y., Shou, J., Zhang, Z.-S., et al. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-01025-y · Cited by 24
“Despite the recent progress that sodium-glucose cotransporter 2 inhibitors (SGLT2is) and/or angiotensin receptor-neprilysin inhibitors (ARNIs) reduced the hospitalization of HFpEF patients [6, 7], HFpEF was still considered to be the greatest unmet need in cardiovascular medicine today, and more efficacious therapies…”
BackgroundCurtain, J. P., Lee, M. M. Y., McMurray, J. J. V., Gardner, R. S., Petrie, M. C., & Jhund, P. S. (2022) · Heart · doi:10.1136/heartjnl-2022-321885 · Cited by 26
“27 The reliability of the relative reduction for HF hospitalisation in patients with HFpEF reported in the CHAM-PION trial is limited by the small number of patients (n=66) included in that analysis.”
BackgroundSelf-citationMerza, N., Akram, M., Mengal, A., Rashid, A. M., Mahboob, A., Faryad, M., Fatima, Z., Ahmed, M., & Ansari, S. A. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101602 · Cited by 26
Sacubitril/Valsartan and Cognitive Outcomes in Heart Failure With Reduced Ejection Fraction
Grewal, P. K., Abboud, A., Myserlis, E. P., Goldschmidt, M., Butler, J., Skopicki, H. A., & Kalogeropoulos, A. P. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100372 · Cited by 26
Booth, D., Davis, J. A., McEwan, P. C., Solomon, S. D., McMurray, J. J. V., de Boer, R. A., Colet, J. C., Bachus, E., & Chen, J. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2940 · Cited by 24
Self-citationHonigberg, M. C., Lau, E. S., Jones, A. D., Coles, A., Redfield, M. M., Lewis, G. D., & Givertz, M. M. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.01.001 · Cited by 25
“Givertz, MD4,5 (1)Cardiology Division, Massachusetts General Hospital, Boston, MA (2)Duke Clinical Research Institute, Duke University, Durham, NC (3)Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (4)Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA (5)Harvard Medical School, Boston,…”
BackgroundSelf-citationLipid in the midst of metabolic remodeling – Therapeutic implications for the failing heart
Nguyễn, T. D., & Schulze, P. C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.08.004 · Cited by 25
Savarese, G., Hage, C., Benson, L., Schrage, B., Thorvaldsen, T., Lundberg, A., Fudim, M., Linde, C. M., Dahlström, U., Rosano, G. M. C., et al. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13165 · Cited by 25
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., Redfield, M. M., Rouleau, J. L., van Veldhuisen, D. J., Zannad, F., Zile, M. R., Desai, A. S., Claggett, B., Jhund, P. S., Boytsov, S. A., Comin-Colet, J., Cleland, J., Düngen, H.-D., Goncalvesova, E., Katova, T., Kerr Saraiva, J. F., Lelonek, M., Merkely, B., Senni, M., Shah, S. J., Zhou, J., Rizkala, A. R., Gong, J., Shi, V. C., & Lefkowitz, M. P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., M.A.P., A.S.D., B.C.); the British Heart Foundation Cardiovascular Research Centre (J.J.V.M., P.S.J.) and the Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Well-being (J.C.), University of Glasgow, Glasgow, and the National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London (J.C.) — all in the United Kingdom; University of...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Anand, Inder S.
- Ge, Junbo
- Lam, Carolyn S.P.
- Maggioni, Aldo P.
- Packer, Milton
- Pfeffer, Marc A.
- Pieske, Burkert
- Redfield, Margaret M.
- Rouleau, Jean L.
- Zannad, Faiez
- Zile, Michael R.
- Desai, Akshay S.
- Claggett, Brian
- Jhund, Pardeep S.
- Boytsov, Sergey A.
- Cleland, John
- Düngen, Hans-Dirk
- Lelonek, Małgorzata
- Senni, Michele
- Shah, Sanjiv J.
- Zhou, Jingmin
- Rizkala, Adel R.
- Gong, Jianjian
- Shi, Victor C.
- Lefkowitz, Martin P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-24
- Volume
- 381
- Issue
- 17
- Pages
- 1609-1620
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2971294569
- Cited by
- 2,430
- References
- 25
- Citations by year
- 2026: 258 · 2025: 296 · 2024: 338 · 2023: 361 · 2022: 414 · 2021: 385 · 2020: 318 · 2019: 55
- FWCI
- 211.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Research Bank (Australian Catholic University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- sacubitril/valsartan, valsartan, angiotensin receptor-neprilysin inhibition, heart failure with preserved ejection fraction, heart failure hospitalization, cardiovascular mortality, NYHA functional class, renal function, Kansas City Cardiomyopathy Questionnaire, natriuretic peptides, structural heart disease, drug safety, adverse events, anemia of chronic kidney disease, hyperkalemia
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angioedema, Biphenyl Compounds, Cardiovascular Diseases, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Hypotension, Male, Middle Aged, Quality of Life, Sex Factors, Stroke Volume, Tetrazoles, Neprilysin, Single-Blind Method, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.